Eisai

News

Closeup of X-ray photography of human brain

Biogen, Eisai hit hard as Alzheimer’s drug is abandoned

The dwindling number of amyloid-targeting drugs in development for Alzheimer’s disease (AD) has been reduced by one more, after Biogen and Eisai pulled the plug on aducanumab.

News

Eisai, Takeda and GARDP hunt for new antibiotics

The not-for-profit Global Antibiotic Research and Development Partnership has joined forces with Eisai and Takeda to search for new antibiotics.

Views & Analysis

Taking on the challenge of childhood epilepsy

Japan’s Eisai has a long-term commitment to treating epilepsy, with a series of therapies already on the market - but with many different forms of the disease, requiring different therapeutic appro

News

The liver is a vital organ of the digestive system present in vertebrates and some other animals. It has a wide range of functions, including detoxification, protein synthesis, and production of biochemicals necessary for digestion.

Eisai/Merck & Co's Lenvima approved in EU for first line liv...

The European Commission has approved Eisai/Merck & Co's Lenvima as a new first-line treatment for liver cancer.

News

Biogen and Eisai Alzheimer's drug excites doctors, but not i...

Investors spooked after string of failures

News

PureTech to research Alzheimer's drugs based on 'brain drain...

US biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases such as Alzheimer’s are linked to drainage issues in the brain.

Biogen, Eisai hit hard as Alzheimer’s drug is abandoned

Eisai, Takeda and GARDP hunt for new antibiotics

Taking on the challenge of childhood epilepsy

Eisai/Merck & Co's Lenvima approved in EU for first line liv...

Biogen and Eisai Alzheimer's drug excites doctors, but not i...

PureTech to research Alzheimer's drugs based on 'brain drain...

AZ claims another win for Imfinzi in frontline liver cancer

Using AI-driven synthetic personas to take your insights fur...

Eisai

Editor's Picks